Caligan Partners LP 13F: Portfolio & Holdings
This page tracks the 13F filings for Caligan Partners LP (SEC CIK 0001727492), a NEW YORK-based hedge fund managing $1.40 billion across 24 reported positions as of Q1 2026, per its quarterly SEC Form 13F-HR filing. The Q1 2026 13F filing shows 97.7% of Caligan's reported portfolio concentrated in Healthcare.
By portfolio weight, the top holdings are LIQUIDIA CORPORATION (LQDA) at 21.67%, ABIVAX S.A. (ABVX) at 11.51%, and REVOLUTION MEDICINES INC (RVMD) at 11.37%. Ranked by the share of each peer fund's 13F equity portfolio that overlaps with Caligan's disclosed positions as of Q1 2026, the closest peers are Paradigm Biocapital Advisors 13F (28.8%), Commodore Capital 13F (17.4%), and Darwin Global Management 13F (14.8% overlap).
Most recently, the manager opened a new position in SPYRE THERAPEUTICS, INC. (SYRE) (3.13%), fully exited INHIBRX BIOSCIENCES INC (INBX) , added to XENON PHARMACEUTICALS INC (XENE) (+153.43% shares), and trimmed TANGO THERAPEUTICS INC (TNGX) (-35.42% shares). View the full Q1 2026 allocation shift and trading report →
- 13F AUM
- $1.4B
- Equity Positions
- 24
- Top-10 Concentration
- 78.9%
- Largest Sector · 97.7%
- Healthcare
- Longest-Held Position · 14 qtrs
- ANIK
- Median Holding Period
- 3 Qtrs
Top 10 Holdings — Caligan — Q1 2026
Largest 13F positions disclosed by Caligan, ranked by portfolio weight. Full multi-quarter history and the broader institutional holder base for each ticker linked per row.
| # | Issuer | Ticker | Sector | Weight | Position Value | Detail |
|---|---|---|---|---|---|---|
| 1 | LIQUIDIA CORPORATION | LQDA | Healthcare | 21.67% | $306.4M | Position History All Holders |
| 2 | ABIVAX S.A. | ABVX | Healthcare | 11.51% | $162.8M | Position History All Holders |
| 3 | REVOLUTION MEDICINES INC | RVMD | Healthcare | 11.37% | $160.7M | Position History All Holders |
| 4 | VAXCYTE INC | PCVX | Healthcare | 8.47% | $119.7M | Position History All Holders |
| 5 | XENON PHARMACEUTICALS INC | XENE | Healthcare | 5.73% | $81.0M | Position History All Holders |
| 6 | MINERALYS THERAPEUTICS INC | MLYS | Healthcare | 5.31% | $75.1M | Position History All Holders |
| 7 | EXELIXIS INC | EXEL | Healthcare | 4.71% | $66.6M | Position History All Holders |
| 8 | TANGO THERAPEUTICS INC | TNGX | Healthcare | 3.56% | $50.4M | Position History All Holders |
| 9 | TYRA BIOSCIENCES INC | TYRA | Healthcare | 3.46% | $48.9M | Position History All Holders |
| 10 | SPYRE THERAPEUTICS, INC. NEW | SYRE | Healthcare | 3.13% | $44.3M | Position History All Holders |
View Caligan's Q1 2026 allocation shift and trading report →
Portfolio composition
Sectors, concentrations, and a tap-through treemap of every position in the fund's latest 13F.
Quarterly shiftsQ1 2026 vs previous quarter
Top movers in Caligan's Form 13F versus the prior reporting quarter. Δ Weight is the change in portfolio weight (percentage points); Δ Shares is the percent change in share count.
| Company | Ticker | Δ Weight | Δ Shares |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | XENE | +3.47% | +153.43% |
| INVENTIVA SA | IVA | +1.10% | +148.75% |
| VOR BIOPHARMA INC | VOR | +1.52% | +108.10% |
| AVALO THERAPEUTICS INC | AVTX | +0.26% | +85.47% |
| ADMA BIOLOGICS INC | ADMA | +-2.00% | +57.89% |
| Company | Ticker | Δ Weight | Δ Shares |
|---|---|---|---|
| TANGO THERAPEUTICS INC | TNGX | 0.54% | -35.42% |
| Company | Ticker | New weight |
|---|---|---|
| SPYRE THERAPEUTICS, INC.NEW | SYRE | 3.13% |
| LB PHARMACEUTICALS INC.NEW | LBRX | 2.45% |
| SAB BIOTHERAPEUTICS INCNEW | SABS | 2.16% |
| OPUS GENETICS INCNEW | IRD | 1.96% |
| MBX BIOSCIENCES INCNEW | MBX | 1.79% |
| Company | Ticker | Prev weight |
|---|---|---|
| INHIBRX BIOSCIENCES INC | INBX | 2.34% |
| RAPT THERAPEUTICS INC | SYN_75382E208 | 2.00% |
| SPRUCE BIOSCIENCES INC | SPRB | 0.16% |
| ELEDON PHARMACEUTICALS INC | ELDN | 0.08% |
Waterfall analysis
Top movers versus the prior reporting quarter. Left panel bridges market-value change in USD millions; right panel shows share-count change in %.
Holding period analytics
Distribution of holding periods for all 46 stocks the fund has ever held (up to selected quarter):
Which Funds Hold a Similar Portfolio to Caligan?
Ranked by percentage of the peer fund's 13F equity portfolio that overlaps with Caligan's positions in Q1 2026.
| # | Fund | Shared Positions | Overlap % |
|---|---|---|---|
| 1 | Paradigm Biocapital Advisors 13F | 9 | 28.8% |
| 2 | Commodore Capital 13F | 6 | 17.4% |
| 3 | Darwin Global Management 13F | 2 | 14.8% |
| 4 | Frazier Life Sciences 13F | 6 | 12.4% |
| 5 | Vestal Point Capital 13F | 4 | 12.2% |
How Has Caligan's AUM Changed Over Time?
Quarterly 13F-reported AUM for Caligan, derived from aggregate reported position market values disclosed to the U.S. SEC.
| Quarter | 13F AUM (USD) | QoQ Change |
|---|---|---|
| Q4 2022 | $126M | — |
| Q1 2023 | $143M | +0.02B |
| Q2 2023 | $165M | +0.02B |
| Q3 2023 | $196M | +0.03B |
| Q4 2023 | $297M | +0.10B |
| Q1 2024 | $378M | +0.08B |
| Q2 2024 | $428M | +0.05B |
| Q3 2024 | $315M | -0.11B |
| Q4 2024 | $395M | +0.08B |
| Q1 2025 | $479M | +0.08B |
| Q2 2025 | $515M | +0.04B |
| Q3 2025 | $721M | +0.21B |
| Q4 2025 | $1.1B | +0.37B |
| Q1 2026 | $1.4B | +0.32B |
Methodology & FAQ
How We Track Caligan Holdings
Our data is systematically aggregated directly from quarterly Form 13F-HR disclosures submitted to the U.S. Securities and Exchange Commission (SEC).
- Who Must File (Reporting Threshold): This dataset includes filings from U.S. institutional investment managers, hedge funds, mutual funds, university endowments, and family offices managing at least $100 million in Section 13(f) securities (including equities, options, convertibles, ETFs, and warrants).
- What is Included (Data Scope): By regulation, 13F filings include long positions in U.S. exchange-listed stocks, ETFs, shares of closed-end investment companies, and convertible debt, as defined in the SEC's official Section 13(f) securities list . For listed options (calls/puts) the reported value is based on the notional value.
- Portfolio Weight Explained (Metric Definition): “Portfolio Weight” shows how much of a fund's total reported 13F portfolio value (excluding listed options) is allocated to a specific position on the reporting date.
- How to Use This Data (Interpretation): Quarter-over-quarter changes in shares and portfolio weight reflect a combination of active trading and market price movements. These are descriptive metrics of fund allocation, not explicit buy or sell signals.
What does Caligan's 13F filing disclose about their portfolio?
A Form 13F-HR filed by Caligan with the U.S. SEC discloses all long positions in Section 13(f) securities — U.S.-listed equities, ETFs, closed-end funds, and listed put/call options — held at quarter-end with a market value of at least $200,000 or 10,000 or more shares. Pactolio aggregates these filings to surface Caligan’s reported portfolio weights, share counts, and quarter-over-quarter allocation shifts in a structured format. The filing represents a point-in-time snapshot of disclosed long-side exposure, not a real-time or complete view of the fund’s total book.
How do you measure conviction in Caligan's portfolio allocations?
Conviction is measured by portfolio weight — the percentage of Caligan’s total reported 13F market value allocated to a given position — rather than by absolute share count or dollar value alone. A position representing a disproportionately large share of the fund’s disclosed book signals high-conviction allocation, regardless of whether it ranks among the fund’s largest absolute holdings. Tracking how that weight changes quarter-over-quarter separates active reallocation decisions from passive price appreciation drift.
What is excluded from Caligan's 13F — short positions, swaps, and derivatives?
SEC Form 13F requires disclosure of long positions only. Specifically excluded are: short interest, total return swaps, credit default swaps, and all OTC derivatives — none of which appear in 13F filings regardless of position size. Listed put and call options must be disclosed but are excluded from portfolio weight calculations on this platform so that reported weights reflect direct equity exposure and remain comparable across filers. This means Caligan’s 13F represents the reported long book, which may differ materially from its net economic exposure.
When is Caligan's 13F data available, and how large is the reporting lag?
Investment managers must submit Form 13F within 45 calendar days of each quarter-end (the T+45 deadline). Pactolio ingests filings directly from SEC EDGAR as they are published — managers who file early appear in our system before the deadline, while late filers are captured on their actual filing date. The quarter label shown at the top of this page reflects the most recently processed 13F cycle for Caligan. The inherent reporting lag means the data always reflects positions as of the prior quarter-end, not current holdings.
Who must file a Form 13F with the SEC, and does Caligan qualify?
Under SEC Rule 13f-1, any investment manager — including hedge funds, family offices, registered investment advisers, pension funds, and university endowments — that exercises investment discretion over $100 million or more in Section 13(f) securities at any point during a calendar year must file Form 13F for that year. Caligan meets this threshold, which is why its holdings are publicly disclosed and accessible on this platform. The $100 million threshold is evaluated on a rolling basis, meaning new filers can enter and existing filers can exit the disclosure regime as AUM crosses that boundary.